Plataforma de Cribado de Fármacos e Farmacoxenómica
REACT-EU PROJECT
CONVENIO DE COLABORACIÓN ENTRE A AXENCIA GALEGA DE INNOVACIÓN E A UNIVERSIDADE DE SANTIAGO DE COMPOSTELA PARA REGULAR AS CONDICIÓNS DA AXUDA DESTINADA Á ACTUALIZACIÓN E AMPLIACIÓN DA PLATAFORMA INNOPHARMA DA USC
Click para máis Info
As infraestruturas de alta capacidade de INNOPHARMA ofrecen un conxunto de servizos que cobren todas as etapas do proceso de descubrimento temperán de fármacos, desde a identificación de dianas ata a avaliación preliminar de seguridade e toxicidade. A plataforma está dispoñible tanto para servizos á carta como para proxectos complementarios de colaboración no descubrimento de fármacos.
Drug discovery program design
- Candidate Target Profile definition
- Feasibility/druggability assessment
- Screening cascade design
- Identification of hits, leads and candidates
Assay development, miniaturization, and automation
- Target-based assays
- Phenotypic assays
- Deconvolution assays
- Custom assays
De-risking programs
- Drug discovery programs up to proof of concept stage
Chemical compound libraries
- Compounds selected in silico based on biological and structural diversity
- Proprietary compounds
- Drug repurposing libraries
- Target-focused sub-libraries
Pharmacogenomics studies
- Biomarkers identification
- Identification of novel therapeutic targets
In vitro preliminary ADME-Tox and safety
- Cytochrome P450 induction and inhibition
- Cytotoxicity
- hERG channel
- Chemical, microsomal and plasma stability
- Plasma protein binding
- Permeability assay
- P-glycoprotein
- Genotoxicity
Customized assay development
- Target engagement
- Phenotypic assays
- Deconvolution assays
From INNOPHARMA we are constantly developing new tests and implementing new technologies, so if you have any interest in any test or technology not included in this list, please contact us
COVID-19
|
|
ACE2 activity TMPRSS2 activity Furin activity |
TARGET-BASED
-
GPCRs
| Radioligand Assays |
|
|
| Second Messengers |
|
|
Isolated Organ Assays |
|
|
| Beta-Arrestin Translocation - BRET |
|
|
|
|
Radioligand Assays |
|
|
|
|
|
|
|
|
|
|
|
PHENOTYPIC ASSAYS
|
|
|
|
|
|
|
PRELIMINARY ADME-Tox AND SAFETY ASSAYS
-
CITOTOXICITY
| Cell Lines |
|
|
|||||||||
| Cell Viability Technologies |
|
|
|||||||||
|
|
|
|
||||||||
|
|
|
|
||||||||
|
|
|
|
|
|
||||||
|
|
|
|
|
|
||||||
|
|
|
CUSTOMIZED ASSAYS
|
|
|
The Innopharma Platform has state-of the art equipment for carrying out assay development projects and screening campaigns with different technological approaches
- Radioactivity (Filtration and SPA)
- Absorbance
- Fluorescence intensity and polarization
- Luminescence
- FRET and Homogeneous Time-Resolved Fluorescence
- BRET
- Alphascreen
- Fluorescence Lifetime Imaging
- Automated patch-clamp
- Label free (Dynamic Mass Redistribution)
- Automated mobility shift (Lab on a chip)
- High Content Screening
- UPLC-MS/MS
- Genome wide and candidate gene association studies
- Next Generation Sequencing
Plataforma de Cribado de Fármacos e Farmacoxenómica INNOPHARMA
- CIMUS
- Avenida de Barcelona, s/n, 15782Santiago de Compostela
- 881 815 459
- innopharma [at] usc.es